Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SU14813 是一种多靶点受体酪氨酸激酶抑制剂,能够抑制 VEGFR2 (IC50:50 nM),VEGFR1 (IC50:2 nM),PDGFRβ (IC50:4 nM),KIT (IC50:15 nM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 289 | 现货 | ||
2 mg | ¥ 412 | 现货 | ||
5 mg | ¥ 662 | 现货 | ||
10 mg | ¥ 1,180 | 现货 | ||
25 mg | ¥ 2,160 | 现货 | ||
50 mg | ¥ 3,530 | 现货 | ||
100 mg | ¥ 4,970 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 728 | 现货 |
产品描述 | SU14813 is a multi-receptor tyrosine kinase inhibitor with potent antiangiogenesis and antitumor activity (IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT). |
靶点活性 | PDGFRβ:4 nM , c-Kit:15 nM, VEGFR1:2 nM , VEGFR2:50 nM |
体外活性 | SU14813, a small molecule identified from the same chemical library used to isolate sunitinib, has broad-spectrum RTK inhibitory activity through binding to and inhibition of VEGFR, PDGFR, KIT, and FLT3.?In cellular assays, SU14813 inhibited ligand-dependent and ligand-independent proliferation, migration, and survival of endothelial cells and/or tumor cells expressing these targets.?SU14813 inhibited VEGFR-2, PDGFR-beta, and FLT3 phosphorylation in xenograft tumors in a dose- and time-dependent fashion[1]. |
体内活性 | The plasma concentration required for in vivo target inhibition was estimated to be 100 to 200 ng/mL.?Used as monotherapy, SU14813 exhibited broad and potent antitumor activity resulting in regression, growth arrest, or substantially reduced growth of various established xenografts derived from human or rat tumor cell lines.?Treatment in combination with docetaxel significantly enhanced both the inhibition of primary tumor growth and the survival of the tumor-bearing mice compared with administration of either agent alone[1]. |
分子量 | 442.48 |
分子式 | C23H27FN4O4 |
CAS No. | 627908-92-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 44 mg/mL (99.44 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.26 mL | 11.2999 mL | 22.5999 mL | 56.4997 mL |
5 mM | 0.452 mL | 2.26 mL | 4.52 mL | 11.2999 mL | |
10 mM | 0.226 mL | 1.13 mL | 2.26 mL | 5.65 mL | |
20 mM | 0.113 mL | 0.565 mL | 1.13 mL | 2.825 mL | |
50 mM | 0.0452 mL | 0.226 mL | 0.452 mL | 1.13 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SU14813 627908-92-3 Angiogenesis Tyrosine Kinase/Adaptors VEGFR PDGFR c-Kit SU-14813 Inhibitor SU 14813 Vascular endothelial growth factor receptor CD117 Platelet-derived growth factor receptor inhibit SCFR inhibitor